Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28208618 | 1.00 | TSHR (0.52) | TSHRTRPA1MIFTAAR1KDM4E | |
| SCHEMBL7039581 | 1.00 | TSHR (0.52) | TSHRTRPA1MIFTAAR1KDM4E | |
| SCHEMBL156029 | 1.00 | TSHR (0.52) | TSHRTRPA1MIFTAAR1KDM4E | |
| SCHEMBL909548 | 0.97 | TRPA1 (0.50) | TSHRTRPA1MIFTAAR1KDM4E | |
| SCHEMBL954845 | 0.86 | PTGS2 (0.48) | TSHRTRPA1ALDH1A1 | |
| SCHEMBL6565095 | 0.86 | ESR1 (0.43) | TSHRTRPA1ALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL11144946 | 0.84 | PBRM1 (0.45) | TSHRTRPA1TAAR1KDM4EADRA2A | |
| SCHEMBL5324135 | 0.84 | PTGS2 (0.56) | TSHRKDM4ECYP2D6LMNAHIF1A | |
| SCHEMBL28153074 | 0.84 | TRPA1 (0.39) | TSHRTRPA1TAAR1KDM4ELMNA | |
| SCHEMBL9079901 | 0.81 | CTSK (0.48) | TSHRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | claimed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | claimed |
| EP-2327767-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-29 | — | — | EP | claimed |
| EP-2327765-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-01 | — | — | EP | claimed |
| US-20130177949-A1 | NITRILASES | VERENIUM CORPORATION (US) | 2013-07-11 | — | — | US | claimed |
| EP-2327767-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | claimed |
| EP-2327766-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | claimed |
| EP-2327765-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | claimed |
| EP-2319919-A1 | Nitrilases | Verenium Corporation (US) | 2011-05-11 | — | — | EP | claimed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | claimed |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | DIVERSA CORPORATION | 2003-07-03 | — | — | US | claimed |
| WO-2023150374-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
| CN-109486897-A | A kind of method that stereoselectivity enzymatic hydrolysis splits 2- phenylpropionic acid enantiomer | 湖南理工学院 | 2019-03-19 | — | — | CN | disclosed |
| US-20180194747-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | BOEHRINGER INGELHEIM INT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20040002147-A1 | Nitrilases | DIVERSA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003097810-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | DIVERSA CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-5258305-A | Manufacture of optically active 2-phenylpropionic acid and 2-phenylpropionamide from the nitrile using Rhodococcus equi | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-11-02 | — | — | US | disclosed |
| US-5258305-A | Manufacture of optically active 2-phenylpropionic acid and 2-phenylpropionamide from the nitrile using Rhodococcus equi | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194747-A1 | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof | SCNN1B, SCNN1A, TRPM5 | TSHR 4441/4885TRPA1 9/4885MIF 2672/4885 |
| US-20040002147-A1 | Nitrilases | RNGTT, DNTT, NOP2 | TSHR 4001/4885TRPA1 2778/4885MIF 3707/4885 |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | NIT2, DNPH1, ASNS | TSHR 4562/4885TRPA1 2608/4885MIF 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.